3/5
08:08 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
3/5
06:08 am
ntla
Intellia Therapeutics initiated with a Buy at H.C. Wainwright
Low
Report
Intellia Therapeutics initiated with a Buy at H.C. Wainwright
3/5
06:08 am
ntla
Intellia Therapeutics initiated with a Buy at H.C. Wainwright
Low
Report
Intellia Therapeutics initiated with a Buy at H.C. Wainwright
2/28
04:39 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
2/28
04:39 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
2/28
02:10 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/28
02:10 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/28
12:21 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/28
12:21 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/28
10:16 am
ntla
Rating for NTLA
Low
Report
Rating for NTLA
2/28
08:06 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $13.00 price target on the stock, down previously from $45.00.
Medium
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) had its "neutral" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $13.00 price target on the stock, down previously from $45.00.
2/28
06:58 am
ntla
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
2/28
06:58 am
ntla
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
2/28
06:58 am
ntla
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Intellia Therapeutics downgraded to Sell from Neutral at Goldman Sachs
2/28
06:48 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
2/27
06:23 pm
ntla
Intellia Therapeutics downgraded to Neutral from Overweight at JPMorgan
Medium
Report
Intellia Therapeutics downgraded to Neutral from Overweight at JPMorgan
1/27
08:02 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
1/27
08:02 am
ntla
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
Low
Report
Intellia Therapeutics, Inc. (NASDAQ: NTLA) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating. They now have a $11.00 price target on the stock, down previously from $56.00.
1/27
06:40 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/27
06:40 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
1/27
04:55 am
ntla
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Medium
Report
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
1/27
04:55 am
ntla
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Medium
Report
Intellia Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley